CamBMT1: A proof-of-principle phase 1b / randomised phase 2 study of afatinib penetration into brain metastases (mets) for patients undergoing neurosurgical resection, both with and without prior low-dose, targeted radiotherapy
Authors:
- R. BairdRBR. Baird
- J. Garcia-CorbachoJGJ. Garcia-Corbacho
- N. RamenatteNRN. Ramenatte
- A. JonsonAJA. Jonson
- S. AhmadSAS. Ahmad
- D.-M. SmithDSD.-M. Smith
- W. QianWQW. Qian
- S. KumarSKS. Kumar
- C. LinossiCLC. Linossi
- T. MatysTMT. Matys
- M. GravesMGM. Graves
- D. JodrellDJD. Jodrell
- 11 October 2016
- journal article
- Published by Elsevier in Annals of Oncology
- Vol. 27, vi132